期刊
ADVANCED SCIENCE
卷 9, 期 22, 页码 -出版社
WILEY
DOI: 10.1002/advs.202105077
关键词
5-FU resistance; gastric cancer; lncRNAs; nanoparticles; p53 signaling pathway
资金
- National Natural Science Foundation of China [81772514, 82073381]
- Pearl River S&T Nova Program of Guangzhou [201806010005]
- Natural Science Foundation of Guangdong [S2019B151502046]
- China Postdoctoral Science Foundation [2021TQ0381, 2021M703700]
Chemoresistance is a major challenge in gastric cancer treatment. This study identifies a novel lncRNA TMEM44-AS1 related to 5-FU resistance and develops a new nanocarrier CGE for efficient delivery of si-TMEM44-AS1, leading to the reversal of 5-FU resistance and enhanced therapeutic effect in a mouse model.
Chemoresistance is one of the leading causes of therapeutic failure in gastric cancer (GC) treatment. Recent studies have shown lncRNAs play pivotal roles in regulating GC chemoresistance. Nanocarriers delivery of small interfering RNAs (siRNAs) to silence cancer-related genes has become a novel approach to cancer treatment research. However, finding target genes and developing nanosystems capable of selectively delivering siRNAs for disease treatment remains a challenge. In this study, a novel lncRNA TMEM44-AS1 that is related to 5-FU resistance is identified. TMEM44-AS1 has the ability to bind to and sponge miR-2355-5p, resulting in the upregulated PPP1R13L expression and P53 pathway inhibition. Next, a new nanocarrier called chitosan-gelatin-EGCG (CGE) is developed, which has a higher gene silencing efficiency than lipo2000, to aid in the delivery of a si-TMEM44-AS1 can efficiently silence TMEM44-AS1 expression to synergistically reverse 5-FU resistance in GC, leading to a markedly enhanced 5-FU therapeutic effect in a xenograft mouse model of GC. These findings indicate that TMEM44-AS1 may estimate 5-FU therapy outcome among GC cases, and that systemic si-TMEM44-AS1 delivery combined with 5-FU therapy is significant in the treatment of patients with recurrent GC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据